key: cord-0700493-3gnkbak1
authors: Foti, Rosario; Amato, Giorgio; Elis, Visalli
title: SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor
date: 2020-07-01
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.110040
sha: 368c06c83444edd37bf448f7641abd293657bc38
doc_id: 700493
cord_uid: 3gnkbak1

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. (4). We report a case of a 57 year old man with psoriatic arthritis treated with Methotrexate and Secukinumab who in April 2020 reports fever, dyspnea, agenusia, anosmia and conjunctivitis ; he was tested for SARS-CoV-2 and he resulted positive. For the rapid worsening of clinical symptoms, the patient was hospitalized, intubated and treated with mechanical ventilation and antiviral therapy. There was a gradual and progressive improvement with extubation and subsequent discharge. Biohumoral tests documented lymphocytopenia and increase of reactants of the acute phase with IL 6 levels always normal. In our case reports, unlike what reported by Balestri, IL 17 inhibitor was not protective against the progression of the infection, resulting in ARDS (Acute distress respiratory Syndrome). In this patients low IL 6 values were found , at all stages of the disease, suggesting that other cytokines and mechanisms may have a role in critical COVID-19 patients which progress to multiple organ dysfunction.

May IL-17 have a role in COVID-19 infection? Med Hypotheses

Tocilizumab treatment in COVID-19: a single center experience

Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function

Girardelli CR SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor

All authors declare to not have conflict of interest as well as funding sources to declare.